The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...

DelveInsight’s 'Complement Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline complement inhibitors in various stages of clinical development, major ...

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

"Atypical Hemolytic Uremic Syndrome Pipeline"Following the success of terminal complement inhibitors like eculizumab and ravulizumab, the therapeutic focus in 2025 has shifted towards developing ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...

(MENAFN- GlobeNewsWire - Nasdaq) The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as ...